

# Dapagliflozin

## Catalog No: tcsc0781



### Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



### Specifications

**CAS No:**

461432-26-8

**Formula:**

$C_{21}H_{25}ClO_6$

**Pathway:**

Membrane Transporter/Ion Channel

**Target:**

SGLT

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 100$  mg/mL (244.58 mM)

**Alternative Names:**

BMS-512148

**Observed Molecular Weight:**

408.87


## Product Description

Dapagliflozin (BMS-512148) is a sodium-glucose co-transporter 2 (**SGLT2**) inhibitor for the treatment of type 2 diabetes.

IC50 & Target: SGLT2<sup>[1]</sup>

**In Vitro:** Dapagliflozin pretreatment of hypoxic HK2 cells significantly improves the cell viability in a dose-dependent manner. Dapagliflozin decreases Bax expression, the Bax/Bcl2 ratio, and PARP expression in hypoxic HK2 cells<sup>[2]</sup>.

**In Vivo:** At 11 mM glucose, dapagliflozin raises glucagon release from 18% to 32% of control, while the effect of dapagliflozin addition is minor at 1 mM glucose. At the intermediate glucose concentration of 6 mM, glucagon secretion is estimated to be 24% and 30% of control in the absence or presence of dapagliflozin, respectively<sup>[1]</sup>. Dapagliflozin pretreatment significantly reduces the number of TUNEL-positive cells in IR-injured kidneys. Dapagliflozin pretreatment significantly elevates the HIF1 expression in IR-injured renal tubular cells from mice<sup>[2]</sup>. Dapagliflozin (10 mg/kg, o.p.) causes a marked increase in urinary glucose in SGLT2i-mice. Dapagliflozin acutely suppresses BAT thermogenesis by reducing sympathetic nerve activity. Dapagliflozin enhances hepatic gluconeogenesis and glycogenolysis<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!